- Sanofi and GlaxoSmithKline said they were in 'advanced discussions' with the European Commission to supply up to 300m doses of a Covid-19 vaccine.

The vaccine candidate developed by Sanofi in partnership with GSK was based on recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK's adjuvant technology.

The doses would be manufactured in European countries including France, Belgium, Germany and Italy.

'This marks a key milestone in protecting and serving the European population against Covid-19,' GSK said.

'The partners plan to provide a significant portion of total worldwide available supply capacity in 2021/22 to the global initiative,' it added.

Story provided by